Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

[1]  A. Pardi,et al.  A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[3]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[4]  Napoleone Ferrara,et al.  VEGF as a Therapeutic Target in Cancer , 2005, Oncology.

[5]  G. Jayson,et al.  Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. , 2005, Current opinion in molecular therapeutics.

[6]  Sheila A Doggrell,et al.  Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration , 2005, Expert opinion on pharmacotherapy.

[7]  M. Blumenkranz,et al.  Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. , 2005, Ophthalmology.

[8]  Kenneth D Anderson,et al.  Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. , 2005, Molecular vision.

[9]  Zhen-ping Zhu,et al.  Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. , 2005, Frontiers in bioscience : a journal and virtual library.

[10]  H. Hurwitz,et al.  Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. , 2005, Seminars in oncology.

[11]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[12]  Zhen-ping Zhu,et al.  Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C , 2004, Journal of Cell Science.

[13]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[14]  B. Ruggeri,et al.  Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. , 2004, Current medicinal chemistry.

[15]  Peter Bohlen,et al.  Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity* , 2003, Journal of Biological Chemistry.

[16]  P. Bohlen,et al.  Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. , 2003, The Journal of clinical investigation.

[17]  S. Rafii,et al.  Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity , 2003, Leukemia.

[18]  G. Vrensen,et al.  Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.

[19]  P. Bohlen,et al.  Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey. , 2002, Endocrinology.

[20]  P. Bohlen,et al.  Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. , 2002, Current cancer drug targets.

[21]  Joan W. Miller,et al.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.

[22]  D. S. Mcleod,et al.  Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. , 2002, Investigative ophthalmology & visual science.

[23]  P. Bohlen,et al.  Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy , 2002, International journal of cancer.

[24]  Anne P. Mclaughlin,et al.  Role of PLCγ and Ca2+ in VEGF- and FGF-induced choroidal endothelial cell proliferation , 2001 .

[25]  D. Mukhopadhyay,et al.  Tyrosine Residues 951 and 1059 of Vascular Endothelial Growth Factor Receptor-2 (KDR) Are Essential for Vascular Permeability Factor/Vascular Endothelial Growth Factor-induced Endothelium Migration and Proliferation, Respectively* , 2001, The Journal of Biological Chemistry.

[26]  D. Hicklin,et al.  Monoclonal antibody strategies to block angiogenesis. , 2001, Drug discovery today.

[27]  D. Weng,et al.  Angiozyme: A Novel angiogenesis inhibitor , 2001, Current oncology reports.

[28]  M. Shibuya.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.

[29]  I. Zachary,et al.  Vascular endothelial growth factor-induced prostacyclin production is mediated by a protein kinase C (PKC)-dependent activation of extracellular signal-regulated protein kinases 1 and 2 involving PKC-delta and by mobilization of intracellular Ca2+. , 2001, The Biochemical journal.

[30]  P. Bohlen,et al.  Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies* , 2000, The Journal of Biological Chemistry.

[31]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[32]  T. Veikkola,et al.  VEGFs, receptors and angiogenesis. , 1999, Seminars in cancer biology.

[33]  M. Shibuya,et al.  VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells , 1999, Oncogene.

[34]  D. Hicklin,et al.  Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. , 1999, Cancer letters.

[35]  B. Keyt,et al.  Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.

[36]  D. Hicklin,et al.  Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. , 1998, Cancer research.

[37]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[38]  D. Bates,et al.  Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. , 1997, The American journal of physiology.

[39]  M. Shibuya,et al.  The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts , 1997, Oncogene.

[40]  V. Bautch,et al.  Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. , 1996, Cancer research.

[41]  D. Donner,et al.  Vascular Endothelial Cell Growth Factor Promotes Tyrosine Phosphorylation of Mediators of Signal Transduction That Contain SH2 Domains , 1995, The Journal of Biological Chemistry.

[42]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[43]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Liu,et al.  Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.

[45]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[46]  N. Ferrara.  The role of VEGF in the regulation of physiological and pathological angiogenesis. , 2005, EXS.

[47]  Joan W. Miller,et al.  Anti-Vascular Endothelial Growth Factor Strategies for the Treatment of Choroidal Neovascularization From Age-Related Macular Degeneration , 2004, International ophthalmology clinics.

[48]  R. Bjercke,et al.  KDR activation is crucial for VEGF165-mediated Ca2+ mobilization in human umbilical vein endothelial cells. , 1999, The American journal of physiology.